LPL Financial LLC Sells 805 Shares of Glaukos Co. (NYSE:GKOS)

LPL Financial LLC decreased its position in Glaukos Co. (NYSE:GKOS) by 6.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,612 shares of the medical instruments supplier’s stock after selling 805 shares during the quarter. LPL Financial LLC’s holdings in Glaukos were worth $1,891,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in GKOS. IFP Advisors Inc bought a new stake in shares of Glaukos in the fourth quarter worth $43,000. Asset Planning Inc bought a new position in shares of Glaukos during the fourth quarter worth about $90,000. Picton Mahoney Asset Management acquired a new position in shares of Glaukos in the fourth quarter worth approximately $125,000. SBI Securities Co. Ltd. bought a new stake in Glaukos in the fourth quarter valued at approximately $153,000. Finally, Smartleaf Asset Management LLC increased its position in Glaukos by 275.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier’s stock valued at $164,000 after purchasing an additional 807 shares during the period. Institutional investors own 99.04% of the company’s stock.

Insider Buying and Selling at Glaukos

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the sale, the insider now directly owns 72,437 shares of the company’s stock, valued at $10,658,380.18. The trade was a 4.50 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares of the company’s stock, valued at approximately $5,708,568.04. This trade represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Piper Sandler dropped their target price on shares of Glaukos from $180.00 to $165.00 and set an “overweight” rating on the stock in a report on Tuesday. Stifel Nicolaus boosted their price objective on Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, December 31st. Truist Financial cut their target price on Glaukos from $185.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, April 11th. Wells Fargo & Company lifted their target price on Glaukos from $153.00 to $160.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Finally, Mizuho upgraded Glaukos from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $140.00 to $200.00 in a report on Wednesday, February 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $158.25.

Glaukos Trading Up 1.7 %

NYSE:GKOS opened at $94.52 on Wednesday. The company has a market cap of $5.35 billion, a PE ratio of -32.94 and a beta of 0.88. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The company has a 50 day simple moving average of $111.68 and a two-hundred day simple moving average of $132.18. Glaukos Co. has a 12 month low of $77.91 and a 12 month high of $163.71.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The business had revenue of $105.50 million for the quarter, compared to the consensus estimate of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. Research analysts forecast that Glaukos Co. will post -1.08 earnings per share for the current year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.